166 related articles for article (PubMed ID: 22085444)
1. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
2. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
4. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
5. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with monoclonal antibodies to epidermal growth factor receptor.
Calvo E; Rowinsky EK
Curr Oncol Rep; 2005 Mar; 7(2):96-103. PubMed ID: 15717942
[TBL] [Abstract][Full Text] [Related]
7. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
Snyder LC; Astsaturov I; Weiner LM
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
[TBL] [Abstract][Full Text] [Related]
8. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
[TBL] [Abstract][Full Text] [Related]
9. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
[TBL] [Abstract][Full Text] [Related]
10. The effects of somatic mutations on EGFR interaction with anti-EGFR monoclonal antibodies: Implication for acquired resistance.
Tabasinezhad M; Omidinia E; Talebkhan Y; Omrani MD; Mahboudi F; Ghaedi H; Wenzel W
Proteins; 2020 Jan; 88(1):3-14. PubMed ID: 31228284
[TBL] [Abstract][Full Text] [Related]
11. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
12. A molecular view of anti-ErbB monoclonal antibody therapy.
Leahy DJ
Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
[TBL] [Abstract][Full Text] [Related]
13. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
14. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab.
Rivera F; Vega-Villegas ME; Lopez-Brea MF; Marquez R
Acta Oncol; 2008; 47(1):9-19. PubMed ID: 18097777
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
Gridelli C; Maione P; Ferrara ML; Rossi A
Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
[TBL] [Abstract][Full Text] [Related]
16. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
Dechant M; Weisner W; Berger S; Peipp M; Beyer T; Schneider-Merck T; Lammerts van Bueren JJ; Bleeker WK; Parren PW; van de Winkel JG; Valerius T
Cancer Res; 2008 Jul; 68(13):4998-5003. PubMed ID: 18593896
[TBL] [Abstract][Full Text] [Related]
17. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
18. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425.
Kamat V; Donaldson JM; Kari C; Quadros MR; Lelkes PI; Chaiken I; Cocklin S; Williams JC; Papazoglou E; Rodeck U
Cancer Biol Ther; 2008 May; 7(5):726-33. PubMed ID: 18424917
[TBL] [Abstract][Full Text] [Related]
19. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives.
Zhu Z
Acta Pharmacol Sin; 2007 Sep; 28(9):1476-93. PubMed ID: 17723181
[TBL] [Abstract][Full Text] [Related]
20. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K
Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]